Moleculin Biotech (NASDAQ:MBRX) has got investors on the edge of their seats. On Monday, April 22, the company said it made a “significant discovery” for lung cancer and will be discussing it on a conference call this Wednesday, April 24. On the news, MBRX stock shot up in premarket trade.
Now, at 2:38 PM, MBRX stock is up more than 150%.
MBRX Stock in the CloudsMoleculin Biotech is a clinical stage pharmaceutical company based in Houston, Texas. MBRX has an extensive portfolio of oncology drug candidates, candidates primarily used for the treatment of ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.